Clinical Trial VICCPHI1065


A phase IA, multicenter, open-label dose escalation study of oral BYL719, in adult patients with advanced solid malignancies, whose tumors have an alteration of the PIK3CA gene

Principal Investigator(s)

Jordan Berlin


  • Protocol No. VICCPHI1065
  • Open Date: 02/01/2011
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: To determine the MTD (or RP2D) of oral BYL719 as single agent in adult patients with advanced solid malignancies whose tumors have a mutation of the PIK3CA gene.
  • Disease Sites: Phase I
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: BYL719
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01219699
  • Secondary Protocol No: CBYL719X2101



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.